Clinical trials: Crow's Feet
Lateral Canthal Lines
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
- Trial name
- NCT03911102
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT04985916
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 19 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthal Lines (LCL), Perioral Rhytids
A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines
This study will serve to collect and analyze additional data on the use of the device croma revitalis for treatment of fine lines on the face including LCL and PR in the routine practice and as "real-world" performance.
- Trial name
- RICHER (NCT07492277)
- Where
- Austria
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Croma-Pharma GmbH
Lateral Canthal Lines, Crow's Feet
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.
- Conditions
- Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
- Trial name
- NCT01124565
- Testing
- RT001
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, Crow's Feet Lines
Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
This is a postmarketing surveillance study in Korea to evaluate the safety and effectiveness of BOTOX® for lateral canthal lines (crow's feet lines) with or without simultaneous glabellar lines.
- Trial name
- NCT02248844
- Testing
- Botulinum Toxin Type A
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Allergan
Skin Aging
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
- Trial name
- NCT01940991
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Revance Therapeutics, Inc.
Crow's Feet Lines
MEDITOXIN® in Treatment of Crow's Feet Line
to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line
- Trial name
- NCT03317574
- Testing
- botulinum toxin type A
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Medy-Tox
Crow's Feet Lines, Glabellar Lines
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.
- Trial name
- NCT03184363
- Testing
- Clostridium Botulinum A Toxin
- Volunteers
- 102 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.